Mirum Pharmaceuticals Inc. (MIRM) has sought FDA approval to expand the use of its lead drug Livmarli in treating progressive familial intrahepatic cholestasis and a decision is expected on March 13, 2024.Progressive Familial Intrahepatic Cholestasis (PFIC) is a rare inherited disorder characterized by impaired bile flow and progressive liver disease.Livmarli is already approved in the U.S. and Europe to treat cholestatic pruritus in patients with Alagille syndrome.For full-year 2023, the company expects Livmarli net products sales to range between $141 million and $143 million, representing approximately 89% year-over-year growth.MIRM closed Tuesday's (Feb.27, 2024) trading at $29.61, up 1.89%.